Stakeholder Opinions: Cystic Fibrosis : BharatBook.com

[Bharatbook]

Stakeholder Opinions: Cystic Fibrosis

Introduction

Approximately 50,000 cystic fibrosis patients worldwide still await a cure of their disease (WHO, 2004). Gene therapy experienced its first failure in 2005 therefore focusing attention on new strategies such as ion channel modulation. In the meantime, the administration of current drugs is improving, which should advance general patient-compliance.

Scope of this Stakeholder Opinions: Cystic Fibrosis report

Discusses disease background in detail, providing insight into cystic fibrosis epidemiology, etiology and symptoms
Examines current diagnosis and treatment trends, providing physicians' opinions with regard to mucolytics, antibiotics, and anti-inflammatory drugs
Defines the main unmet needs regarding the lack of cure, method of drug administration, and the need for new antibiotics
Examines the cystic fibrosis pipeline by type of treatment, including a short discussion of each pipeline product
Research and analysis highlights
Although initially controversial, neonatal screening recommended by the Cystic Fibrosis Foundation and CDC is likely to become more widespread especially due to recent evidence that early diagnosis and intervention extends a better outcome.

Extended antibacterial use due to increasing life-expectancy brings colonization with drug resistant P. aeruginosa, S. aureus and B. cepacia. Beyond the continued concerns with these prevalent pathogens, others such as non-tuberculosis mycobacteria and Stenotrophomonas maltophilia are increasingly in the minds of treating experts.

After the first failure of gene therapy, the realization that treatment leading to cure is an unachievable goal drives limited research and development towards disease modification and symptomatic treatments. Datamonitor identified 15 ongoing cystic fibrosis related projects most of which were in Phase II clinical trials.

Key reasons to read this Stakeholder Opinions: Cystic Fibrosis report

Gain insight into the disease background and issues in the current diagnosis and treatment of cystic fibrosis through key opinion leader comments
Review the unmet needs and the clinical and commercial factors driving new product decisions
Identify the opportunities and threats presented by the cystic fibrosis pipeline and predict future trends in the market .

For more information kindly visit: Bharatbook dot com